Provided by Tiger Trade Technology Pte. Ltd.

Prime Medicine, Inc.

3.90
+0.400011.43%
Post-market: 3.84-0.0570-1.46%19:20 EDT
Volume:11.20M
Turnover:42.66M
Market Cap:703.99M
PE:-3.59
High:4.02
Open:3.36
Low:3.30
Close:3.50
52wk High:6.85
52wk Low:2.67
Shares:180.51M
Float Shares:116.00M
Volume Ratio:2.26
T/O Rate:9.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0853
EPS(LYR):-1.3521
ROE:-373.29%
ROA:-46.52%
PB:17.68
PE(LYR):-2.88

Loading ...

Prime Medicine Doses First Patient in Trial of Investigational Wilson Disease Treatment

MT Newswires Live
·
Oct 05

Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of Pm577a for H1069q-Mutated Wilson Disease

THOMSON REUTERS
·
Oct 05

Prime Medicine, - Initial Clinical Data from Pm577a Trial Expected in 2027

THOMSON REUTERS
·
Oct 05

Prime Medicine, - Pm577 Granted Rare Pediatric Disease Designation by U.S. FDA

THOMSON REUTERS
·
Oct 05

Prime Medicine's PM647 Clears Key Regulatory Hurdle, Oppenheimer Says

MT Newswires Live
·
Sep 26

Prime Medicine Price Target Maintained with a $7.00/Share by Chardan Capital

Dow Jones
·
Sep 25

Costco Wholesale, Scholastic and 3 Stocks to Watch Heading Into Friday

Benzinga Earnings
·
Sep 25

Chardan Capital Sticks to Their Buy Rating for Prime Medicine, Inc. (PRME)

TIPRANKS
·
Sep 25

Stocks to Watch: Akamai, Scholastic, Prime Medicine

Dow Jones
·
Sep 25

Analysts Are Bullish on Top Healthcare Stocks: Arcus Biosciences (RCUS), Prime Medicine, Inc. (PRME)

TIPRANKS
·
Sep 25

Prime Medicine Shares Jump on FDA Clearance for Investigational New Drug Application

Dow Jones
·
Sep 25

Prime Medicine announces FDA clearance of IND application for PM647

TIPRANKS
·
Sep 25

Prime Medicine Wins FDA IND Clearance for PM647 in Alpha-1 Antitrypsin Deficiency

Reuters
·
Sep 25

Prime Medicine, - Initial Clinical Data for Pm647 Expected in 2027

THOMSON REUTERS
·
Sep 25

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for Pm647 in Alpha-1 Antitrypsin Deficiency

THOMSON REUTERS
·
Sep 25

Prime Medicine Set for Fireside Chats at H.C. Wainwright, Morgan Stanley Healthcare Conferences

Reuters
·
Sep 03

Prime Medicine Price Target Maintained with a $7.00/Share by Chardan Capital

Dow Jones
·
Aug 25

Chardan Capital Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)

TIPRANKS
·
Aug 25

Prime Medicine Price Target Maintained with a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 10

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cresco Labs (OtherCRLBF), Prime Medicine, Inc. (PRME) and Steris (STE)

TIPRANKS
·
Aug 07